Thuja Capital

Thuja Capital operates as an early-stage venture capital firm, specializing in investments within the life sciences sector across Europe. The firm deploys deep sector-specific knowledge, entrepreneurial insight, and an extensive network spanning academia, industry, and clinical research to identify and cultivate promising companies poised for significant impact. Their strategic approach involves early investment and active partnership to accelerate the development of groundbreaking scientific innovations.

The firm was established in 2006 by Harrold van Barlingen. His foundational insight stemmed from recognizing a critical gap in early-stage funding and specialized support for nascent life science ventures in Europe. Van Barlingen aimed to bridge this divide, enabling the translation of scientific discoveries into tangible healthcare advancements through targeted capital and strategic guidance.

Thuja Capital’s clientele comprises innovative, product-focused life science companies throughout Europe, often led by visionary CEOs with ambitious goals. The firm’s overarching mission is to drive transformative change in healthcare by meticulously selecting and nurturing companies from their early stages, ultimately bringing vital scientific breakthroughs to patient populations and advancing medical frontiers.